Publication | Open Access

Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy

Surgical OncologyUrologyGenitourinary CancerMedicineDisparate OutcomesCancer GenomicsMuscle-invasive Bladder CancerCisplatin-based Neoadjuvant ChemotherapyCancer TreatmentOncologyRadiation Oncology